Barely Significant
← all excerpts

Lumacaftor-ivacaftor in the treatment of cystic fibrosis: design, development and place in therapy.

Drug Des Devel Ther · 2019 · PMC6650604 · PMID 31409974

Europe PMCDOI
1
hedged sentence
0.0010
closest p · 0.0× alpha
0.0010
boldest claim

The sentences

highly significantP <0.001actually significant
The Phase III studies reported a modest, but highly significant ( P <0.001) mean absolute improvement in FEV1% of 2.6–4.0% compared to placebo at 24 weeks.

also in 132,142 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.